Get started
Author

Xin Sun

Rapid stabilisation of atherosclerotic plaque with 5-aminolevulinic acid-mediated sonodynamic therapy
2015 · Liping Wang, Tengyu Wang, et al. · Thrombosis and Haemostasis · 39
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al. · Clinical Cancer Research · 16
Resveratrol in animal models of pancreatitis and pancreatic cancer: A systematic review with machine learning
2025 · Wenhao Cai, Ziyu Li, et al. · Phytomedicine · 14
Deciphering single-cell transcriptomic landscape of tumors in colorectal cancer treated with photothermal semiconducting polymers to design the combination therapy with checkpoint blockades for inhibition of tumor progression and metastasis
2024 · Haitao Yuan, Yunmeng Bai, et al. · Nano Today · 8
Supplementary Table S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S4 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Data from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S8 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S5 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Table S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Table S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S3 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Works count: 18
Citation count: 77
H-index: 4
I10-index: 3
Year
Topic
Type